Abstract: ObjectiveTo investigate the expression and clinical significance of long noncoding RNA SBF2AS1 (SBF2 antisense RNA 1) in nonsmall cell lung cancer (NSCLC). MethodsRealtime quantitative polymerase chain reaction (qRTPCR) was used to detect SBF2AS1 expressions in 114 cases of NSCLC tissues and the adjacent normal tissues to analyze its relationship with clinicpathological characteristics, diagnostic value and prognosis in NSCLC. Results SBF2AS1 expression was significantly higher in the NSCLC (4.336±0.032) compared with the adjacent normal tissues (1.256±0.021), with a significant difference (t=3.594, P=0.005). The expression of SBF2AS1 was related with tumor size (χ2=13.072, P=0.001), lymphatic metastasis (χ2=6.896, P=0.009), TNM stage (χ2=8.566, P=0.003), smoking history (χ2=8.769, P=0.003) and infiltration degree (χ2=17.852, P=0.001), but was not related with age (χ2=0.141, P=0.707), sex (χ2=0.036, P=0.850) and pathological type (χ2=1.267, P=0.260). The area under the receiver operating characteristic (ROC) curve was 0.853 (95%CI: 0.7550.879, P=0.004). The sensitivity and specificity was 52.4% and 87.8%, respectively. The difference betwen low SBF2AS1 expression and high SBF2AS1 expression groups was statistically significant in overall survival time (42.3 months vs. 25.2 months, χ2=4.753, P=0.013). ConclusionThe expression of SBF2AS1 is upregulated in NSCLC and may be proved useful as a biomarker and diagnostic target for the treatment of patients with NSCLC.

Key words: Lung neoplasms, Pathology, clinical, Biomarkers, pharmacological, SBF2-AS1